Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06337305 · ClinicalTrials.gov registry record
Resiliency in Patients Undergoing Radical Cystectomy for Bladder Cancer
A clinical trial of Bladder Cancer, sponsored by University of Kansas Medical Center.
- Completed
- Registry status
- 74
- Enrollment target
- 1
- Study location
NCT06337305 is a study of Bladder Cancer that has completed, run by University of Kansas Medical Center. The registered enrollment target is 74 participants, below the 12,753-participant average among 175 other Bladder Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06337305, a study of Bladder Cancer, has completed, sponsored by University of Kansas Medical Center.
- COMPLETED
- Registry status
- 74 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective cross-sectional survey-based study composed of both a retrospective chart review and 3-series patient survey. This study will help elicit potential areas throughout the perioperative course of radical cystectomy to improve patient resilience and quality of life, providing opportunity for future interventional studies.
Conditions Studied
Study Locations (1)
Kansas
- University of Kansas Medical Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2020-08-19 |
| Est. Completion | 2023-08-19 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06337305
The ClinicalTrials.gov registry entry for NCT06337305 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,753-participant average among 175 other Bladder Cancer trials with a reported enrollment target (99% lower). The listed sponsor is University of Kansas Medical Center, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bladder Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT06337305 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.
Frequently Asked Questions
What is clinical trial NCT06337305 about?
NCT06337305 is a clinical study titled "Resiliency in Patients Undergoing Radical Cystectomy for Bladder Cancer". This is a prospective cross-sectional survey-based study composed of both a retrospective chart review and 3-series patient survey. This study will help elicit potential areas throughout the perioperative course of radical cystectomy to improve patient resilience and quality of life, providing oppor...
What is the current status of trial NCT06337305?
This trial is currently completed. The enrollment target is 74 participants. The study started on 2020-08-19. Estimated completion is 2023-08-19.
What conditions does trial NCT06337305 study?
This clinical trial studies the following conditions: Bladder Cancer.
Who is sponsoring clinical trial NCT06337305?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06337305 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy
RECRUITING · NA
-
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
RECRUITING · Phase 1
-
CONFIRM: Magnetic Resonance Guided Radiation Therapy
RECRUITING · NA
-
Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support
RECRUITING · NA
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.